UK-Based Biotech Submits Patent for Transformational Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD)

Genflow has announced that it has filed a new patent application with the US Patent and Trademark Office that relates to variants of Sirtuin-6, and the gene variant’s therapeutic uses for the treatment of two disorders involving the liver: NAFLD, and non-alcoholic steatohepatitis.